Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2026)
Vivos Therapeutics (VVOS) reported Non-Current Debt of $418000.0 for Q1 2026, down 10.87% on a QoQ basis from $469000.0 in Q4 2025.
Vivos Therapeutics (VVOS) has 4 years of Non-Current Debt data on file, last reported at $418000.0 in Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $418000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418000.0 (changed N/A YoY) and the FY2025 annual result came in at $469000.0, changed N/A from the prior year.
- Non-Current Debt fell to $418000.0 in Q1 2026 per VVOS's latest filing, from $469000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $8.4 million in Q3 2025 and bottomed at $418000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 29.64 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 14.22 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 27.88 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 10.99 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 598.50 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 8.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.13 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 1.81 Bn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 418,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 418,000.00 |
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Sep 30, 2025 | 8.38 Mn |
| Sep 30, 2025 | 8.38 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2021 | 105,906.00 |
| Mar 31, 2021 | 105,906.00 |
| Dec 31, 2020 | 423,000.00 |
| Dec 31, 2020 | 423,000.00 |